These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36282934)

  • 21. The landscape of checkpoint inhibitors in oncology.
    Haslam A; Kim MS; Elbaz J; Prasad V
    Eur J Cancer; 2024 Sep; 209():114240. PubMed ID: 39084136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises.
    Hey SP; Gyawali B; D'Andrea E; Kanagaraj M; Franklin JM; Kesselheim AS
    J Natl Cancer Inst; 2020 Apr; 112(4):335-342. PubMed ID: 31651981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy.
    Ranganathan S; Haslam A; Tuia J; Prasad V
    J Cancer Policy; 2024 Mar; 39():100462. PubMed ID: 38061492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
    Khozin S; Blumenthal GM; Jiang X; He K; Boyd K; Murgo A; Justice R; Keegan P; Pazdur R
    Oncologist; 2014 Jul; 19(7):774-9. PubMed ID: 24868098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
    Arora S; Narayan P; Osgood CL; Wedam S; Prowell TM; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Ghosh S; Philip R; Ison G; Berman T; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2022 Mar; 28(6):1072-1086. PubMed ID: 34711632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between health-related quality-of-life results, outcomes of efficacy and drug approvals: a meta-research study of randomized phase III trials in oncology.
    Paratore C; Zichi C; Schiavone R; Caglio A; Gamba T; Bombaci S; Vellani G; Marandino L; Perrone F; Di Maio M
    ESMO Open; 2024 Aug; 9(8):103654. PubMed ID: 39067259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
    Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
    J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.
    Conde-Estévez D; Tusquets I; Servitja S; Martínez-García M; Salas E; Albanell J
    Anticancer Drugs; 2014 Oct; 25(9):992-7. PubMed ID: 24892723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
    Liberti L; Stolk P; McAuslane JN; Schellens J; Breckenridge AM; Leufkens H
    Oncologist; 2015 Jun; 20(6):683-91. PubMed ID: 25948678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
    Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
    Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
    Woodford RG; Zhou DD; Kok PS; Lord SJ; Friedlander M; Marschner IC; Simes RJ; Lee CK
    Cancer; 2022 Apr; 128(7):1449-1457. PubMed ID: 34985773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
    Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
    Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
    Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
    Jardim DL; Schwaederle M; Wei C; Lee JJ; Hong DS; Eggermont AM; Schilsky RL; Mendelsohn J; Lazar V; Kurzrock R
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26378224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
    Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
    JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.
    Adunlin G; Cyrus JW; Dranitsaris G
    Breast Cancer Res Treat; 2015 Dec; 154(3):591-608. PubMed ID: 26596731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strength of statistical evidence for the efficacy of cancer drugs: a Bayesian reanalysis of randomized trials supporting Food and Drug Administration approval.
    Pittelkow MM; Linde M; de Vries YA; Hemkens LG; Schmitt AM; Meijer RR; van Ravenzwaaij D
    J Clin Epidemiol; 2024 Oct; 174():111479. PubMed ID: 39047916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.